Genome-wide analysis of primary CD4+ and CD8+ T cell transcriptomes shows evidence for a network of enriched pathways associated with HIV disease

Jing Qin Wu1, Dominic E Dwyer2, Wayne B Dyer3, Yee Hwa Yang4, Bin Wang1, Nitin K Saksena1*

Abstract

Background: HIV preferentially infects CD4+ T cells, and the functional impairment and numerical decline of CD4+ and CD8+ T cells characterize HIV disease. The numerical decline of CD4+ and CD8+ T cells affects the optimal ratio between the two cell types necessary for immune regulation. Therefore, this work aimed to define the genomic basis of HIV interactions with the cellular transcriptome of both CD4+ and CD8+ T cells.

Results: Genome-wide transcriptomes of primary CD4+ and CD8+ T cells from HIV+ patients were analyzed at different stages of HIV disease using Illumina microarray. For each cell subset, pairwise comparisons were performed and differentially expressed (DE) genes were identified (fold change >2 and B-statistic >0) followed by quantitative PCR validation. Gene ontology (GO) analysis of DE genes revealed enriched categories of complement activation, actin filament, proteasome core and proton-transporting ATPase complex. By gene set enrichment analysis (GSEA), a network of enriched pathways functionally connected by mitochondria was identified in both T cell subsets as a transcriptional signature of HIV disease progression. These pathways ranged from metabolism and energy production (TCA cycle and OXPHOS) to mitochondria mediated cell apoptosis and cell cycle dysregulation. The most unique and significant feature of our work was that the non-progressing status in HIV+ long-term non-progressors was associated with MAPK, WNT, and AKT pathways contributing to cell survival and anti-viral responses.

Conclusions: These data offer new comparative insights into HIV disease progression from the aspect of HIV-host interactions at the transcriptomic level, which will facilitate the understanding of the genetic basis of transcriptomic interaction of HIV in vivo and how HIV subverts the human gene machinery at the individual cell type level.

Background

HIV preferentially infects CD4+ T cells and the functional impairment and numerical decline of CD4+ and CD8+ T cells characterize HIV disease. The numerical decline of CD4+ and CD8+ T cells affects the optimal ratio between the two cell types necessary for immune regulation. This ratio can predict the progression or non-progression to HIV disease [1]. In HIV+ non-progressing individuals, who control viremia in the absence of antiviral therapy, polyclonal, persistent, and vigorous HIV-1-specific CD4+ T cell proliferative responses are present, resulting in the elaboration of interferon and antiviral chemokines [2]. HIV disease progression leads to a wide range of defects in CD4+ T cell function, such as altered profiles of cytokine production [3], weak or absent HIV-specific CD4+ T cell proliferation [4,5], dysregulation of CD4+ T cell turnover [6], and impaired production of new cells [7,8]. The cytotoxic and non-cytotoxic antiviral arms of CD8+ T cells are potent in controlling HIV replication [9]. The non-cytotoxic activity including chemokines, soluble CD8 antiviral factor, urokinase-type plasminogen activator, and antiviral membrane-bound factor suppresses HIV transcription in an antigen-independent and major histocompatibility complex-unrestricted manner [10]. The induction of memory cytotoxic CD8+ T cells in early HIV infection, particularly Gag-specific cells, helps control viral replication and is associated with slower CD4+ T cell
Host cytolytic effector responses appear to delay the disease progression [12]. In HIV disease progression, numerical decline and functional impairment of CD8+ T cells can be attributed to increased susceptibility to apoptosis from alterations in the cytokine milieu in lymphoid tissue, bystander effects from neighboring productively infected CD4+ T cells, and toxicity from the release of HIV-derived gp120 or Tat proteins, in addition to direct infection [13,14]. Although the direct and indirect HIV-induced mechanisms leading to CD4+ and CD8+ T cell depletion are known, the genetic basis of these pathogenic mechanisms are uncertain. To better understand HIV pathogenesis at the genomic level, investigators have carried out microarray-based studies of HIV infection, including the use of whole PBMC, cell lines, monocytes, macrophages, T cells, lymphoid and gut tissue [15]. For CD4+ T cells, reports mainly focused on T cell lines in vitro, except for one study reporting resting CD4+ T cells in viremic versus aviremic HIV+ individuals [16]. The limitation of in vitro studies is that they do not reflect effects observed in vivo, as HIV induces T cell dysfunction systemically and affects both the HIV-infected cells and the majority of bystander cells. Studies on CD8+ T cells are limited, and include searching for genes responsible for non-cytotoxic CD8+ T cell activity and comparisons between individuals with high non-cytotoxic activity and uninfected controls [17,18]. Recently, the transcriptional profiling of CD4+ and CD8+ T cells from early infection, chronic infection, and LTNP patients has been reported [19]. Interferon responses as a transcriptional signature of T cells from early and chronically infected patients were identified, but no pronounced difference between early and chronically infected patients, between HIV seronegative controls and LTNP was detected; thus, combined groups had to be used to facilitate further analysis [19].

Using Illumina Human-6 V2 Expression BeadChips encompassing all 27,000 human genes (=48,000 gene transcripts), recently we have successfully identified coordinated up-regulation of oxidative phosphorylation (OXPHOS) genes as a transcriptional signature in CD8+ T cells from the viremic patients on HAART and the possible association between components of MAPK pathway and LTNP status [20]. Further study suggested a correlation between HIV load level and CD8+ T cell transcriptome shift [21], supporting that detection threshold of viral load could be used as an accurate grouping criteria in differentiating HIV disease status. Here, in this study we compared global gene expression profiles of all 25,000 human genes for both primary CD4+ and CD8+ T cells from three HIV+ disease groups along with healthy HIV seronegative controls. The various HIV+ disease groups included long-term non-progressors (LTNPs) and viremic patients on HAART (VIR), as well as aviremic patients on HAART (below detectable levels, BDL). Using Illumina Human-6 V2 Expression BeadChips, comparative genome-wide transcriptomic analysis of ex-vivo collected CD4+ and CD8+ T cells clearly showed evidence for concerted up-regulation of metabolic pathways during HIV disease progression, and a clear correlation between transcriptome shift and detectable plasma viremia uniquely for CD8+ T cells. A novel observation was that HIV non-progression was associated with enriched MAPK, WNT, and AKT pathways. Although both CD4+ and CD8+ T cell transcriptomes showed overlaps at the pathway level, other pathways that segregated these cellular transcriptomes during disease progression were identified, suggesting that HIV also maintains distinct interaction with these cell types in vivo. Detection of such transcriptomic signatures for progressive and non-progressive HIV disease may not only facilitate the understanding of genetic basis of HIV interaction with variety of blood leukocytes but also lead to the development of new biomarkers in predicting disease rates.

Results
Analysis of differentially expressed genes and enriched gene ontology category
CD4+ and CD8+ T cell-derived total cellular RNA from 14 HIV-infected individuals (4 LTNP, 5 BDL and 5 VIR, Table 1) and 5 HIV seronegative (NEG) healthy individuals were hybridized to the Sentrix Human-6 V2 Expression BeadChip (Singapore). After passing quality assessment, data normalization was performed and a linear model fit in conjunction with an empirical Bayes statistics were used to identify candidate DE genes [22,23]. For both CD4+ and CD8+ T cells, pairwise comparisons from the four study groups (BDL versus NEG, VIR versus NEG, LTNP versus NEG, BDL versus LTNP, VIR versus LTNP, BDL versus VIR) were carried out and candidate DE genes with >2-fold change and B-statistic > 0 were identified for each comparison. The number of DE genes identified in each comparison is listed in Table 2 and the list of DE genes for each comparison between HIV+ disease groups are provided in Additional File 1.

To identify the important functional categories from the DE genes, GO Tree was used to identify GO categories with significantly enriched gene numbers (P < 0.01). For BDL versus VIR and VIR versus LTNP comparisons in CD4+ T cells, the GO categories response to stimuli and extracellular region were significantly enriched (p <0.01; Figure 1A and 1B). The sub-tree view under the above categories revealed that both complement activation with contributing genes C1QB, C1QC, and SERPING1, and complement component C1q complex with contributing genes C1QA and C1QB were significantly enriched. For the VIR and LTNP comparison in CD8+ T cells, response to stimuli, catalytic activity,
and cell part were significantly enriched (Figure 1C). Further inspection of these enriched categories showed that at level 7, category cytosol with contributing genes BAG3, PRF1, UNC119, ARFIP1, PSME2, PSMA5, PSMB2, PSMB8, and PSMB10, category actin filament with contributing genes IQGAP1, ACTB, and ACTA2, category proteasome core complex with contributing genes PSMA5, PSMB2, PSMB8, and PSMB10, and category proton-transporting ATPase complex with contributing genes ATP5J2, ATP6V0E1, and ATP6V1 D were significantly enriched (Figure 1D).

Validation of differentially expressed genes

To confirm the DE genes from the Illumina microarray, mRNA expression levels of the selected DE genes from each paired comparison for both CD4+ and CD8+ T cells were measured by quantitative real-time PCR (Table 3). DE genes contributing to the enriched GO categories were randomly selected for real-time PCR confirmation. For CD8+ T cells, these genes included BAG3 in category cytosol, ACTA2 in category actin, PSMB2 and PSMA5 in category proteasome core complex, and ATP6V1 D in category proton-transporting ATPase complex. For CD4+ T cells, C1QB, C1QC, and SERPING1 in category complement activation were selected. DE genes not under any enriched GO categories were also randomly selected. The mRNA from the CD4+ and CD8+ T cells of the same patient at the same time point was used for real-time multiplexed qPCR analysis. The fold changes were evaluated by real-time multiplexed qPCR and were well consistent with the results from differentially expressed genes obtained by microarray (Table 3).

Gene set enrichment analysis

To further unravel the biological mechanisms differentiating between HIV disease groups, pairwise comparisons using GSEA were performed for both CD4+ and CD8+ T cells were measured by quantitative real-time PCR (Table 3). DE genes contributing to the enriched GO categories were randomly selected for real-time PCR confirmation. For CD8+ T cells, these genes included BAG3 in category cytosol, ACTA2 in category actin, PSMB2 and PSMA5 in category proteasome core complex, and ATP6V1 D in category proton-transporting ATPase complex. For CD4+ T cells, C1QB, C1QC, and SERPING1 in category complement activation were selected. DE genes not under any enriched GO categories were also randomly selected. The mRNA from the CD4+ and CD8+ T cells of the same patient at the same time point was used for real-time multiplexed qPCR analysis. The fold changes were evaluated by real-time multiplexed qPCR and were well consistent with the results from differentially expressed genes obtained by microarray (Table 3).

### Table 2 Number of differentially expressed genes in pairwise comparisons for CD4+ and CD8+ T cells (fold change > 2 and B-statistic > 0)

| Differentially expressed genes | CD4 up | CD4 down | CD8 up | CD8 down | CD4 and CD8 up | CD4 and CD8 down |
|-------------------------------|--------|----------|--------|----------|----------------|-----------------|
| BDL vs NEG                    | 50     | 24       | 206    | 72       | 15             | 3               |
| VIR vs NEG                    | 173    | 128      | 477    | 273      | 79             | 48              |
| LTNP vs NEG                   | 5      | 9        | 17     | 6        | 0              | 0               |
| BDL vs LTNP                   | 0      | 3        | 3      | 1        | 0              | 0               |
| VIR vs LTNP                   | 29     | 7        | 118    | 63       | 10             | 2               |
| BDL vs VIR                    | 1      | 8        | 5      | 12       | 0              | 1               |

Up: up-regulation; down: down-regulation; vs: versus; CD4 and CD8: genes differentially expressed in both CD4+ and CD8+ T cells in the same paired comparison.

### Table 1 Patient clinical detail

| Patient | Group | Age | Viral load (copies/ml) | CD4 counts (cells/μl) | CD8 counts (cells/μl) |
|---------|-------|-----|------------------------|-----------------------|-----------------------|
| V1      | VIR   | 46  | 209                    | 500                   | 566                   |
| V2      | VIR   | 41  | 2530                   | 278                   | 845                   |
| V3      | VIR   | 40  | 5710                   | 324                   | 1169                  |
| V4      | VIR   | 43  | 546,000                | 94                    | 312                   |
| V5      | VIR   | 60  | 683,000                | 48                    | 73                    |
| B1      | BDL   | 48  | < 50                   | 450                   | 288                   |
| B2      | BDL   | 63  | < 50                   | 480                   | 360                   |
| B3      | BDL   | 40  | < 50                   | 1065                  | 1065                  |
| B4      | BDL   | 62  | < 50                   | 776                   | 1692                  |
| B5      | BDL   | 59  | < 50                   | 251                   | 548                   |
| L1      | LTNP  | 59  | < 50                   | 630                   | 579                   |
| L2      | LTNP  | 51  | < 50                   | 714                   | 476                   |
| L3      | LTNP  | 79  | < 50                   | 920                   | 900                   |
| L4      | LTNP  | 33  | 57                     | 780                   | 900                   |

V1-5: viremic patients on HAART; B1-5: aviremic patients on HAART; L1-4: long-term non-progressors. All the patients and seronegative controls are males.

Plasma viral load was measured using the Quantiplex HIV RNA3.0 (Chiron bDNA) assay with a lower limit of detection of 50 HIV-1 copies/ml (Chiron Diagnostics, Halstead, United Kingdom).
Figure 1 Gene ontology (GO) tree and bar chart for the enriched GO categories. GO categories with at least 2 genes and p < 0.01 are identified as enriched and colored red in the GOTree. In GOTree, O stands for observed gene number in the category; E for expected gene number in the category; R for ratio of enrichment for the category; and P for p value calculated from the statistical test given for the categories with R > 1 to indicate the significance of enrichment. A. GO tree for the differentially expressed genes in CD4+ T cells between the BDL and VIR groups. B. GO tree for the differentially expressed genes in CD4+ T cells between the VIR and LTNP groups. C. GO tree for the differentially expressed genes in CD8+ T cells between the VIR and LTNP groups. D. Bar chart of level 7 categories under cellular component category for CD8+ T cells between the VIR and LTNP groups.
### Table 3 qPCR validation of differentially expressed genes

| Gene Symbol | Accession No. | Description | Fwd Primer | Fwd Primer Seq | Rev Primer | Rev Primer Seq | Paired Comparison | Cell Type | FC_qPCR | FC_MA |
|-------------|---------------|-------------|------------|----------------|------------|----------------|------------------|-----------|---------|-------|
| KLRD1       | NM_0022622    | killer cell lectin-like receptor subfamily D, member 1 | KLRD1L     | tggaggagatgctgctgc | KLRD1R     | tttgtatataaagttcatagtga | BDL vs LTNP | CD8   | 2.5    | 2.1   |
| IRS2        | NM_0037492    | insulin receptor substrate 2 | IRS2L      | tgtctcttgctccacacatc | IRS2R      | catctcttgcttgaagccaga | BDL vs VIR | CD8   | 3.8    | 2.7   |
| GBP1        | NM_0020532    | guanylate binding protein 1, interferon-inducible | GBP1L      | aggcacacactctgctgc | GBP1R      | tccagagatcatcctgggt | BDL vs LTNP | CD8   | -2.5   | -2.4  |
| ACTA2       | NM_0016131    | actin, alpha 2, smooth muscle, aorta | ACTA2L     | ctgttcagccattctctcat | ACTA2R     | tcatgatgctgttgaggtgt | BDL vs LTNP | CD8   | -1.3   | -2.2  |
| ATP6V1D     | NM_0159942    | ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D | ATP6V1DL   | tttttacctctgtaagccagt | ATP6V1DR   | ggcctttatagcacatgttaggt | VIR vs LTNP | CD8   | 2.0    | 2.8   |
| BAG3        | NM_0042813    | BCL2-associated athanogene 3 | BAG3L      | cagccagaaaaacgtgtgac | BAG3R      | agaggcagctggaagcttg | VIR vs LTNP | CD8   | -1.5   | -2.0  |
| ACTA2       | NM_0016131    | actin, alpha 2, smooth muscle, aorta | ACTA2L     | ctgttcagccattctctcat | ACTA2R     | tcatgatgctgttgaggtgt | VIR vs LTNP | CD8   | -4.3   | -2.8  |
| PSMB2       | NM_0027943    | proteasome subunit, beta type, 2 | PSMB2L     | agaggcagctggaactctt | PSMB2R     | gaaggttggacagctttag | VIR vs LTNP | CD8   | 1.3    | 2.3   |
| PSMA5       | NM_0027902    | proteasome subunit, alpha type, 5 | PSMA5L     | tgaatgcaacaaacattgacg | PSMA5R     | ttctcttgtaacatgttgg | VIR vs LTNP | CD8   | 2.7    | 2.7   |
| C1QB        | NM_004913     | complement component 1, q subcomponent, B chain | C1QBL      | ggctctcagcaagcagcag | C1QBR      | ccatgggatcttcatcata | BDL vs VIR | CD4   | -4.8   | -4.8  |
| C1QC        | NM_172693     | complement component 1, q subcomponent, C chain | C1QCL      | aaggggtggtagctgacgact | C1QCR      | ttctgccctctgggtctct | BDL vs VIR | CD4   | -5.6   | -4.1  |
| SERPING1    | NM_0006622    | serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 | SERPING1L  | tctctcaggctctgctctgt | SERPING1R  | ggatgctcttccaggtgttgg | BDL vs VIR | CD4   | -5.0   | -2.6  |
| C1QB        | NM_004913     | complement component 1, q subcomponent, B chain | C1QBL      | ggctctcagcaagcagcag | C1QBR      | ccatgggatcttcatcata | VIR vs LTNP | CD4   | 6.1    | 6.0   |
| C1QC        | NM_172693     | complement component 1, q subcomponent, C chain | C1QCL      | aaggggtggtagctgactgact | C1QCR      | ttctgccctctgggtctct | VIR vs LTNP | CD4   | 7.3    | 4.4   |
| SERPING1    | NM_0006622    | serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 | SERPING1L  | tctctcaggctctgctctgt | SERPING1R  | ggatgctcttccaggtgttgg | VIR vs LTNP | CD4   | 5.3    | 2.8   |

**Notes:**
- **FC_qPCR:** fold change by qPCR
- **FC_MA:** fold change by microarray.
Metabolic pathways associated with HIV disease progression

In CD4+ and/or CD8+ T cells between HIV+ disease groups, 43 metabolic pathways were significantly up-regulated in the first group in at least one of the above pairwise comparisons when comparing the first (more advanced disease status) to the second group (less advanced disease status) as listed in Table 5. According to the biological function, these 43 pathways were divided into (1) aerobic metabolism; (2) carbohydrate and lipid metabolism; (3) amino acid and nucleotide metabolism; and (4) protein metabolism, respectively. Under each category, the pathways that showed significance across more pairwise comparisons were listed at the top.

In aerobic metabolism, the most generally up-regulated pathways were tricarboxylic acid (TCA) cycle and OXPHOS, central for cell energy production. The OXPHOS pathway was enriched in 5/6 paired comparisons with FDR < 0.05, which reached the most stringent statistical level. Closely associated with OXPHOS pathway is the TCA cycle, which produces immediate precursor (NADH) to OXPHOS to produce ATP. The TCA cycle was up-regulated in 4/6 paired comparisons at the significance level of FDR < 0.1 (FDR cut off value, normally <0.25, more stringently <0.1, most stringently <0.05). To illustrate the up-regulation of TCA cycle in GSEA output, the enrichment plot and heat map of the genes involved in this pathway from the paired comparisons VIR versus LTNP in CD8+ T cells and BDL versus LTNP in CD4+ T cells were shown as representatives in Figure 3.

In the remaining three categories, butanoate and fatty acid metabolism were top listed in carbohydrate and lipid metabolism. The valine, leucine, and isoleucine degradation in nitrogen metabolism and the proteasome involved in protein degradation were the two most significant and generally enriched pathways besides the OXPHOS pathway (FDR < 0.5 in four paired comparisons and FDR < 0.1 in one paired comparison).

Immune-related pathways associated with HIV disease progression

In addition to the metabolic pathways, 39 immune-related gene sets were found to be significantly up-regulated in at least one of the above pairwise comparisons (Table 6; pathways showing significance across more pairwise comparisons are listed at top). Four outstanding groups emerged based on the similarity of biological relevance of these pathways: (1) cell cycle and apoptosis related; (2) cytotoxicity, complement activation, and cell signaling; (3) interleukin and interferon responses; and (4) cytoskeleton and cell adhesion.

In the cell cycle and apoptosis category, five pathways were directly involved in cell apoptosis including chemical pathway, apoptosis, apoptosis_genmapp, caspase pathway, and SA_caspase_cascade (Table 6). In CD8+ T cells, the chemical pathway was significantly enriched (FDR < 0.1) when comparing the VIR group against the BDL/LTNP groups. In the comparison between VIR and BDL, 15/21 genes in this pathway were core enrichment genes associated with the VIR group, including STAT1, BCL2L1, CASP7, TLN1, EIF2S1, BCL2, APAF1, BID, BAX, CASP6, PXN, CASP3, PRKCB1, TP53, and AKT1 (Additional File 2). In CD4+ T cells, the apoptosis pathway was significantly enriched (FDR < 0.1) when comparing the VIR group with the BDL/LTNP groups. In comparing the VIR and LTNP groups, 25/66 genes in this pathway were core enrichment genes associated with the VIR group, such as the death receptor TNFR1 (tumor necrosis factor receptor 1). The cytoplasmic adaptor TRADD, RIP1, and TRAF2, cytoplasmic effector DFF45 and DFF40, effector caspase7, and mitochondrial function genes such as BID and BCL2 (Additional File 2).

In relation to cell cycle, six pathways were significantly up-regulated (four with FDR < 0.05 and two with FDR < 0.1) in CD8+ T cells in the VIR group (versus BDL;
Further inspection of the HSA04110 cell cycle pathway revealed that 54/112 genes were core enrichment genes and the coordinated up-regulation of these genes appears to promote G1 to S transition and induce arrest in G2 to M transition (Figure 5). Coordinately up-regulated genes encoding for proteins promoting G1 to S transition include (1) 2 cyclin dependent kinase (CDK)-cyclin complexes, CDK4/6-cyclin D and CDK2-cyclin E; (2) 2 transcription factors E2F and DP1; (3) DNA biosynthesis complex ORC (origin recognition complex); (4) mini-chromosome maintenance (MCM) complex; (5) CDC25A; and (6) S-phase kinase-associated protein 1 and 2 (SCF and SKP2). Although a few up-regulated genes inhibiting the transition were also
| Gene set name                                      | VvsB_CD8 | VvsB_CD4 | VvL_CD8 | VvL_CD4 | BvsL_CD4 |
|--------------------------------------------------|----------|----------|---------|---------|----------|
| Aerobic metabolism                               |          |          |         |         |          |
| HSA00190_OXIDATIVE_PHOSPHORYLATION               | 0.05     | 0.05     | 0.05    | 0.05    | 0.05     |
| HSA00020_CITRATE_CYCLE                           | 0.1      | 0.1      | 0.1     | 0.1     |          |
| HSA00760_NICOTINATE_AND_NICOTINAMIDE_METABOLISM  | 0.05     | 0.05     | 0.1     | 0.05    |          |
| TYPE_III_SECRETION_SYSTEM                        | 0.05     | 0.05     | 0.05    | 0.05    | 0.05     |
| PHOTOSYNTHESIS                                   | 0.05     | 0.05     | 0.05    | 0.05    | 0.05     |
| ATP_SYNTHESIS                                    | 0.05     | 0.05     | 0.05    | 0.05    | 0.05     |
| FLAGELLAR.Assembly                               | 0.05     | 0.05     | 0.05    | 0.05    | 0.05     |
| MITOCHONDRIAL_FATTY_ACID_BETAOXIDATION           | 0.1      | 0.1      |         |         |          |
| PYRUVATE_METABOLISM                              | 0.1      | 0.05     |         |         |          |
| Carbohydrate and lipid metabolism                |          |          |         |         |          |
| HSA00650_BUTANOATE_METABOLISM                    | 0.05     | 0.1      | 0.05    | 0.05    | 0.05     |
| HSA00671_FATTY_ACID_METABOLISM                   | 0.05     | 0.05     | 0.05    | 0.05    | 0.05     |
| HSA00670_ONE_CARBON_POOL_BY_FOLATE               | 0.1      | 0.1      |         |         |          |
| HSA00051_FRUCTOSE_AND_MANNOSE_METABOLISM         | 0.1      | 0.1      | 0.1     |         |          |
| HSA00511_N_GLUCAN_DEGRADATION                    | 0.05     | 0.05     | 0.05    | 0.05    | 0.05     |
| HSA009030_PENTOSE_PHOSPHATE_PATHWAY              | 0.1      | 0.1      |         |         |          |
| HSA01031_GLUCAN_STRUCTURES_DEGRADATION           | 0.05     | 0.05     |         |         |          |
| STARCH_AND_SUCROSE_METABOLISM                    | 0.05     | 0.05     | 0.1     |         |          |
| HSA00052_GALACTOSE_METABOLISM                    | 0.1      | 0.1      |         |         |          |
| HSA00532_CHONDROTIN_SULFATE_BIOSYNTHESIS         | 0.1      | 0.05     |         |         |          |
| PROPANOATE_METABOLISM                            | 0.05     |          |         |         |          |
| HSA00340_PENTOSE_AND_GLUCURONATE_INTERCONVERSIONS| 0.1      |          |         |         |          |
| HSA001000_GLUCOLYSIS_AND_GLUCONEOGENESIS         | 0.1      |          |         |         |          |
| GLYCOGENESIS                                     | 0.1      |          |         |         |          |
| HSA00710_CARBON_FIXATION                        |          | 0.1      |         |         |          |
| PROSTAGLANDIN_AND_LEUKOTRIENE_METABOLISM         | 0.1      |          |         |         |          |
| BILE_ACID_BIOSYNTHESIS                           | 0.05     |          |         |         |          |
| HSA00531_GLYCOSAMINOLGLYCAN_DEGRADATION           | 0.1      |          |         |         |          |
| HSA00565_Ether_LIPID_METABOLISM                  | 0.1      |          |         |         |          |
| FRUCTOSE_AND_MANNOSE_METABOLISM                  | 0.1      |          |         |         |          |
| Amino acid and nucleotide metabolism             |          |          |         |         |          |
| HSA00280_VALINE_LEUCINE_AND_ISOUCINE_DEGRADATION  | 0.05     | 0.1      | 0.05    | 0.05    | 0.05     |
| LYSINE_DEGRADATION                               | 0.05     | 0.05     | 0.05    | 0.05    | 0.05     |
| HSA00230_PURINE_METABOLISM                       | 0.05     | 0.05     | 0.05    | 0.05    | 0.05     |
| PHENYLALANINE_METABOLISM                         | 0.1      | 0.05     | 0.05    | 0.05    | 0.05     |
| HSA00380_TRYPTOPHAN_METABOLISM                   | 0.1      | 0.05     | 0.05    | 0.05    | 0.05     |
| HSA00240_PYRIDINE_METABOLISM                     | 0.05     | 0.05     | 0.05    | 0.05    | 0.05     |
| HSA00252_ALANINE_AND ASPARTATE_METABOLISM        | 0.1      | 0.1      | 0.1     |         |          |
| HSA00410_BETA_ALANINE_METABOLISM                 | 0.05     | 0.05     | 0.05    | 0.05    | 0.05     |
| PORPHYRIN_AND_CHLOROPHYLL_METABOLISM             | 0.05     | 0.1      | 0.05    | 0.05    | 0.05     |
| HSA00330ARGININE_AND_PROLINE_METABOLISM          | 0.1      |          |         |         |          |
present such as INK4a-d and PCNA, the up-regulation of DNA biosynthesis complexes suggested directly promoted transition. Associated with G2 to M transition, we observed up-regulated genes encoding for proteins that generally prevent the cell cycle, including (1) the protein kinases WEE1 and MYT1, which inactivate the complex CDK1-cyclin B pivotal in regulating G2 to M transition; (2) protein 14-3-3 which inactivates CDC25 phosphatase required for CDK1 activation; (3) DNA-PK activated by DNA damage and CHK kinases which inactivates CDC25; (4) p53 which turns on the expression of GADD45 and 14-3-3σ, both prevent the activity of CDK1-cyclin B.

In the category of cytotoxicity, complement activation and cell signaling, pathways of antigen processing and presentation and cell cytotoxicity were significantly enriched in both CD4+ and CD8+ T cells when the VIR group was compared to the BDL group (FDR < 0.05; Table 6). Three complement-associated pathways COMPPATHWAY, HSA04610 complement and coagulation-cascades, and intrinsic pathway as well as toll receptor signaling pathway were significantly and uniquely enriched in CD4+ T cells of the VIR group (versus BDL/LTNP; FDR < 0.05/0.1; Table 6). Further inspection of HSA04610 pathway revealed 18/68 genes uniquely enriched in both CD4+ and CD8+ T cells when the VIR group was compared to the BDL group. For the same paired comparison, the TIDPATHWAY involved in interferon-γ stimulating anti-viral responses was enriched in CD4+ T cells from the VIR group.

Relatively few pathways were significantly up-regulated in the second group (BDL or LTNP) in pairwise comparisons of the VIR versus BDL, VIR versus LTNP, and BDL versus LTNP groups. However, it was noted that the comparison of BDL versus LTNP in CD4+ T cells gave 7 and 27 pathways enriched in the LTNP group at the statistical level of FDR < 0.05 and FDR < 0.1, respectively (Table 7). Out of these 34 gene sets, 15 were closely associated with the MAPK pathway and 10 with cell signaling such as TCR and chemokine and cytokine pathways. Unique pathways associated with non-progressive HIV disease

Among the 15 MAPK-associated pathways significantly enriched in the LTNP group (BDL versus LTNP) for CD4+ T cells, the NTHI, JNK MAPK, and granule cell survival pathways are the top three gene sets with FDR < 0.05. In the LTNP group, core enrichment genes in the NTHI pathway were MAP2K3 (MEK3) located along the MAPK p38 cascade and NFKBIA associated with NFKB activation (Figure 6, Additional File 2), indicating the up-regulation of p38 pathway. In JNK MAPK and granule cell survival pathway, MAPK9 (JNK2) and its upstream kinase MAP2K7 (MKK7) were found to be core enrichment genes (Figure 6, Additional File 2), indicating the up-regulation of JNK pathway. Overlapping analysis of core enrichment genes between IGF1, insulin, and NGF pathways (FDR<0.05) revealed eight common core enrichment genes (GRB2, PIK3R1, PIK3CA, HRAS, MAP2K1, ELK1, JUN, and FOS). These overlapping genes are involved in the ERK signal transduction cascade, another branch of the MAPK signaling pathway (Figure 6). All the aforementioned MAPK associated pathways are also top ranked in the LTNP group in other pairwise comparisons, although they do not reach the highest statistical significance level (Additional File 4).

In the top ranked but less statistically significant gene sets, AKTPATHWAY and WNT signaling pathways are closely associated with cell survival. Comparing VIR versus LTNP for CD4+ T cells, both pathways were enriched in the LTNP group (FDR = 0.23). In the AKT-PATHWAY, core enrichment genes included PIK3R1, PIK3CA, and PPP2CA involved in AKT activation,
Figure 3 Enrichment plot and heat map for the gene set of tricarboxylic acid cycle by GSEA. A. Enrichment plot for CD8+ T cells from the VIR group (VIR versus LTNP). Bottom, plot of the ranked list of all genes. Y axis, value of the ranking metric; X axis, the rank for all genes. Genes whose expression levels are most closely associated with the VIR or LTNP group get the highest metric scores with positive or negative sign, and are located at the left or right edge of the list. Middle, the location of genes from the gene set TCA cycle within the ranked list. Top, the running enrichment score for the gene set as the analysis walks along the ranked list. The score at the peak of the plot is the enrichment score (ES) for this gene set and those genes appear before or at the peak are defined as core enrichment genes for this gene set. B. Heat map of the genes within the gene set of TCA cycle corresponding to A. The genes that contribute most to the ES, i.e., genes that appear in the ranked list before or at the peak point of ES, are defined as core enrichment genes and highlighted by the red rectangle. Rows, genes; columns, samples. Range of colors (red to blue) shows the range of expression values (high to low). C. Enrichment plot for CD4+ T cells from the BDL group (BDL versus LTNP). D. Heat map of the genes within the gene set of TCA cycle corresponding to C.
transcription factors associated with cell survival NFKB1, NFKB1A, RELA, FOXO1A, and FOXO3A (Additional File 2). In the WNT pathway, some key genes were detected as core enrichment genes including WNT1, WNT10A, WNT10B, FZD6, DVL3, TCF7, and CTNNB1 (β-catenin; Additional File 2).

**Discussion**

An analysis of the CD4+ and CD8+ T cell transcriptomes from three different HIV disease groups was undertaken to identify gene expression signatures associated with disease progression. All the enriched categories derived from GO enrichment analysis of DE genes corresponded to certain enriched pathways detected by GSEA, confirming the statistical reliability of our analyses. For example, the enriched GO category complement activation corresponded to the enriched pathway HSA04610 complement and coagulation cascades in the comparison of VIR versus BDL/LTNP for CD4+ T cells and the enriched GO category proton-transporting ATPase complex corresponded to the enriched OXPHOS pathway in the VIR versus LTNP comparison for CD8+ cells. Also, GSEA detected more comprehensive pathways correlated with disease progression. Among these enriched pathways, mitochondrial function emerged as a major theme during disease progression as a large portion of the enriched pathways for various physiological processes were all closely associated. These pathways, functionally connected to mitochondria, formed a network directly related to HIV disease progression as discussed below (Figure 7).
### Table 6 Enriched gene sets other than involved in energy production

| Gene set name                                                                 | VvsB_CD8 | VvsB_CD4 | VvL_CD8 | VvL_CD4 | BvsL_CD4 |
|-------------------------------------------------------------------------------|----------|----------|---------|---------|----------|
| **Cell cycle and apoptosis related**                                          |          |          |         |         |          |
| CHEMICALPATHWAY                                                              | 0.1      | 0.1      |         |         |          |
| APOPTOSIS                                                                     | 0.1      | 0.1      | 0.1     | 0.1     |          |
| APOPTOSIS_GENMAPP                                                             |          | 0.1      |         |         |          |
| CASPASEPATHWAY                                                                |          | 0.1      | 0.05    |          | 0.05     |
| SA_CASPASE_CASCADE                                                           |          |          | 0.05    | 0.05    | 0.1      |
| DNA_REPLICATION_REACTOME                                                      | 0.05     | 0.05     | 0.1     |          |          |
| G1_TO_S_CELL_CYCLE_REACTOME                                                  | 0.05     |          |         |         |          |
| HSA04110_CELL_CYCLE                                                          |          |          |         |         |          |
| CELL_CYCLE_KEGG                                                              | 0.05     | 0.05     | 0.1     |          |          |
| CBL_LCYLEPATHWAY                                                              | 0.05     |          |         |         |          |
| G2PATHWAY                                                                    | 0.1      |          |         |         |          |
| G1PATHWAY                                                                    | 0.1      |          |         |         |          |
| PS3PATHWAY                                                                   | 0.1      |          |         |         |          |
| MP3PATHWAY                                                                   | 0.1      |          |         |         |          |
| ST_GA12_PATHWAY                                                              |          | 0.05     |         |         |          |
| **Cytotoxicity, complement activation and cell signalling**                  |          |          |         |         |          |
| HSA04612_ANTIGEN_PROCESSING_AND_PRESENTATION                                 | 0.05     | 0.05     | 0.05    | 0.05    |          |
| HSA04650_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY                            | 0.05     | 0.05     | 0.05    |          |          |
| COMIPATHWAY                                                                  | 0.05     | 0.05     | 0.05    | 0.05    | 0.05     |
| HSA04710_Complement_and_coagulation-cascades                                | 0.05     | 0.05     |         |         |          |
| INTRINSICPATHWAY                                                             | 0.1      | 0.1      |         |         |          |
| HSA04620_TOLLLIKE_RECEPTOR_SIGNALING_PATHWAY                                   | 0.05     | 0.1      |         |         |          |
| TOLLPATHWAY                                                                  | 0.05     |          |         |         |          |
| HSA04662_B_CELL_RECEPTOR_SIGNALING_PATHWAY                                    | 0.1      |          |         |         |          |
| SA_B_CELL_RECEPTOR_COMPLEXES                                                  | 0.1      |          |         |         |          |
| **Cytoskeleton and cell adhesion**                                            |          |          |         |         |          |
| RHOPATHWAY                                                                   | 0.05     | 0.05     | 0.05    | 0.05    | 0.05     |
| NDOKDYNAMINPATHWAY                                                           | 0.1      |          |         |         |          |
| SIG_REGULATION_OF_THE_ACTIN_CYTOSKELETON_BY_RHO_GTPASES                      | 0.1      |          |         |         |          |
| INTEGRIN_MEDIATED_CELL_ADHESION_KEGG                                        | 0.1      |          |         |         |          |
| **Interleukin**                                                              |          |          |         |         |          |
| IL12PATHWAY                                                                  | 0.1      |          |         |         |          |
| NO2IL12PATHWAY                                                               | 0.1      |          |         |         |          |
| TIDPATHWAY                                                                   | 0.1      |          |         |         |          |
| IL6PATHWAY                                                                   | 0.1      |          |         |         |          |
| IL3PATHWAY                                                                   | 0.1      |          |         |         |          |
| **Other**                                                                    |          |          |         |         |          |
| SPPAPATHWAY                                                                  | 0.1      |          |         |         |          |
| HSA05120_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_INFECTION           | 0.05     |          |         |         |          |
| HSA05131_PATHOGENIC_ESCHERICHIA_COLI_INFECTION_EPEC                          | 0.1      |          |         |         |          |
| HSA05130_PATHOGENIC_ESCHERICHIA_COLI_INFECTION_EHEC                          | 0.1      |          |         |         |          |
| HSA04320_DORSO_VENTRAL_AXISFORMATION                                          | 0.1      |          |         |         |          |
| HSA05219_BLADDER_CANCER                                                      | 0.1      |          |         |         |          |

VvsB_CD8: Gene sets enriched in the VIR group in the comparison of VIR versus BDL in CD8+ T cells.
VvsB_CD4: Gene sets enriched in the VIR group in the comparison of VIR versus BDL in CD4+ T cells.
VvL_CD8: Gene sets enriched in the VIR group in the comparison of VIR versus LTNP in CD8+ T cells.
VvL_CD4: Gene sets enriched in the VIR group in the comparison of VIR versus LTNP in CD4+ T cells.
BvsL_CD4: Gene sets enriched in the BDL group in the comparison of BDL versus LTNP in CD4+ T cells.

Gene sets significantly enriched are marked by the number 0.05 or 0.1 in the corresponding paired comparisons 0.05: FDR < or = 0.05; 0.1: FDR < or = 0.1.

Gene set information could be searched at the website http://www.broad.mit.edu/gsea/msigdb/search.jsp.
Up-regulated metabolic pathways as a transcriptional signature evoked by mitochondria dysfunction in HIV disease progression

Forty-three up-regulated metabolic pathways were detected as transcriptional signatures in the relatively more advanced HIV cases. These signatures were highlighted by the TCA cycle and OXPHOS pathways along with a series of degradation pathways of carbohydrates, fatty acids, and amino acids, articulating with the TCA cycle by furnishing substrates. Interestingly, this comprehensive and unambiguous expression signature in ex vivo patient-derived T cells is consistent with two recent CD4+ T cell-line-based proteomic studies which also demonstrated the up-regulation of components of OXPHOS, TCA cycle, amino acid metabolism, and fatty acid metabolism at the protein level in human CD4+ T cell lines after HIV infection [26,27]. The proteomic study, using cell lines, and our transcriptome study, using primary patient cells, are complementary, implying the functional significance of our observations. Further, the detection of the OXPHOS pathway as the most significantly enriched gene set for both CD4+ and CD8+ T cells is also in line with earlier work, which identified OXPHOS pathway up-regulation a distinct transcriptional feature in CD8+ T cells unique to the VIR group when compared against the versus the LTNP group [20]. Moreover, by simultaneously comparing both CD4+ and CD8+ T cells from three HIV disease groups, this study further extends previous findings to provide a panoramic view of all the concordantly regulated metabolic pathways in conjunction with OXPHOS pathway. To our knowledge, this study is the first to show this metabolic transcriptional signature in primary CD4+ and CD8+ T cells, in relation to HIV disease progression. We hypothesize that the up-regulation of these metabolic pathways could be a compensatory event evoked by mitochondrial dysfunction incurred by HIV infection and HAART. This hypothesis is based on the fact that mitochondria are the organelles where the
TCA cycle,OXPHOS, and downstream biochemical reactions of degraded products are taking place and mitochondrial dysfunction in HIV disease has been well documented [28]. The NRTIs can inhibit the major mtDNA polymerase [29], induce mtDNA mutations [30], and impair mitochondrial enzymes such as adenylate kinase and the ADP/ATP translocator [31,32]. In addition, the HIV accessory proteins Vpr and Tat, and the HIV protease (Pr) could modulate mitochondrial membrane permeabilization by various pathways involving protein BAX, BAK, BCL-2, and adenine nucleotide translocase (ANT) [33-35].

The hypothesis that metabolic pathways are a compensatory event evoked by mitochondrial dysfunction is further supported by the high similarity between this data and the gene expression profiles from study of compensatory events in primary mitochondrial dysfunction [36]. Using the electron transport chain complex I mutant of Caenorhabditis elegans as a model, 29 up-regulated metabolic pathways characterizing the cellular compensatory events accompanying mitochondrial dysfunction were identified [36], of which 15 (> 50%) were shared with our list.

Pathways involved in mitochondria-mediated cell apoptosis

The significance of mitochondrial dysfunction in HIV disease progression is further strengthened by the detection of coordinately up-regulated genes involved in mitochondria-mediated cell apoptosis in both CD4+ and CD8+ T cells. This is exemplified by the 15 core-enrichment genes in the chemical pathway detected in the CD8+ T cells in the comparison between VIR and BDL groups. For instance, TP53, BAX, and BID could alter the mitochondrial membrane permeability; APAF1 is involved in initiating effector caspase-mediated cell death; CASP3, CASP6, and CASP7 are the effector caspases which cleave substrates leading to modified signaling, and the downstream substrates of these caspases including STAT1, EIF2S1, TLN1 (talin 1), PXN (paxillin), and PRKCB1 (protein kinase C), which eventually lead to cell apoptosis. These genetic level observations were consistent with previous studies at the cellular level showing that the LTNP s had milder mitochondrial impairment and low numbers of cells with reduced mitochondrial membrane potential; this correlates with lower frequency of spontaneous apoptosis and higher frequencies of CD4+ T cells when compared to AIDS patients [37,38].

In addition, the detection of G2 arrest along with the chemical pathway in CD8+ T cells in the VIR group (versus BDL) led to the further speculation that G2 arrest may be functionally linked to mitochondria-mediated cell apoptosis. The HIV protein Vpr induces cell cycle arrest in the G2/M checkpoint in both CD4+ T cells and macrophages [39,40], and there might be a direct correlation between G2 arrest and cell apoptosis [41]. The activation of BAX, the pore-forming mitochondrial protein, has been suggested as the functional linkage between G2 arrest and cell apoptosis [42].

It was unique that in addition to the linkage between G2 arrest and mitochondria-mediated cell apoptosis, the AKT pathway top ranked for the LTNP group (Additional File 4) negatively regulated the chemical pathway by blocking mitochondria-mediated cell apoptosis, which could contribute to cell survival in LTNP s. In the AKT pathway, genes associated with AKT activation including PIK3R1, PIK3CA, and PPP2CA were coordinately up-regulated in the LTNP group (versus VIR) in CD4+ and CD8+ T cells. Activated AKT is known to promote cell survival by phosphorylating BAD and CASP9 to inhibit pore-forming in mitochondria membranes and prevent the subsequent caspase cascade, respectively [43]. Additionally, in the AKT pathway the FOXO factors (FOXO1A, and FOXO3A) detected as core enrichment genes could also contribute to cell survival, as these transcription factors are involved in cell survival [44].

Taken together, a network of pathways closely associated with HIV disease progression was constructed (Figure 7). Centrally located is mitochondrial dysfunction, which interferes with various other pathways.
ranging from metabolism and energy production to cell cycle dysregulation and mitochondria-mediated cell apoptosis. In addition, the mitochondria-mediated cell apoptosis could be blocked by the AKT pathway enriched in the LTNP group. Consistent with our analysis, two large scale studies of HIV-host interactions by siRNA screening also identified a link between mitochondrial function and HIV replication [45,46]. In addition, Zhou et al. have identified the AKT-associated pathway in HIV replication in association with cellular energy metabolism and cell survival, which is well in line with our data.
MAPK pathway enriched uniquely in the LTNP group

The significant up-regulation of gene sets closely associated with three branches of MAPK pathway (ERK, JNK, and p38) in LTNPs could contribute to cell survival as well as stronger anti-HIV responses. In relation to cell differentiation and activation, JNK and p38 are critical for naïve CD4+ T cell differentiation into the Th1 subset, which antagonizes Th2 subset switch associated with HIV disease progression [3]. Activation of the p38 pathway also results in increased IFN-γ production by both CD4+ and CD8+ T cells, plays an important role in T cell homeostasis by selectively inducing CD8+, but not CD4+ T cell death via modulation of BCL-2 expression [47,48]. ERK is required for Th2 differentiation and the cytotoxic activity of most CD8+ T cells [49]. The ERK pathway could be activated by its upstream signaling pathway, the T-cell receptor pathway, which is also up-regulated in the LTNP group. Supporting this speculation, components of TCR complex CD3εpsilon, and ZAP70 (TCR zeta-chain associated protein kinase) as well as genes involved in ERK activation, HRAS (RAS) and MAP2K1 (MEK1), were detected as the core enrichment genes in the T-cell receptor pathway. Further confirmation came from our previous antibody/protein microarray study showing that CD3εpsilon expression was significantly higher in LTNP than in the VIR group on CD4+ T cells [20].

Besides direct involvement, the MAPK pathway interacts with a range of pathways critical for cell function and survival, such as p53 and WNT signaling pathways. The top ranked WNT pathway in the LTNP group (Additional File 4) indicated a possible role of this pathway in cell survival; another study has shown that MAPK-p38 pathway regulates WNT-β-catenin signaling [50].

Critical differences segregating CD4+ and CD8+ T cell transcriptomes during HIV disease

Contrasting with hundreds of differentially expressed genes in CD8+ T cells in the VIR group (versus LTNP), the comparison of BDL versus LTNP revealed only four differentially expressed genes and one enriched gene set, which indicated that the transcriptional profile largely remained unaltered in CD8+ T cells from BDL patients. For the same paired comparison in the CD4+ T cells, although only three differentially expressed genes were detected, 27 enriched gene sets have reached the significance level of FDR < 0.05, which implied the shift of transcriptome profile in CD4+ T cells from BDL patients. Supporting this, an independent study has shown that distinct transcriptional profiles in both CD4+ and CD8+ T cells are established early in HIV infection by comparing between early infection, chronic progressive infection, and non-progression groups [19]. However, the study subjects in this study were grouped by the duration of HIV infection, but not on the plasma HIV load levels (the patients from the early infection group already had detectable viral loads). On the other hand, Hycza’s data demonstrated that with various viral load levels, even if the infection duration was as short as 1-5 months, the CD8+ T cell transcriptional profile could be shifted. Taken together, these datasets appear to show a close correlation between the beginning of detectable plasma viral load and transcriptome shift uniquely in CD8+ T cells. This was not the case for CD4+ T cell transcriptomes. This study, from the gene and gene set level, further confirmed our recent findings that the CD8+ T cell transcriptome profiles shift only...
when a viral load is above the certain as yet unknown threshold level [21].

Another transcriptional signature unique to CD4+ T cells is the complement activation in the VIR group (versus BDL/LTNP) detected by both differentially expressed genes analysis and GSEA. This was exemplified by HSA04610 complement and coagulation-cascade pathway; the coordinately up-regulated core enrichment genes include those encoding for the complement proteins and complement receptors (Additional File 3), but not the lytic pathway genes (C6, 7, 8, 9). This is consistent with studies showing that HIV activates the complement cascades, but avoids the lysis via complement regulatory molecules [51,52]. Interactions between HIV envelope protein gp41 and C1Q lead to the complement activation independent of HIV-specific antibodies [53] and the sequentially generated C3 fragments (C3b, iC3b, and C3d) linked to HIV could have high affinity interaction with complement receptors on a wide range of cells such as B cells, macrophages, and follicular dendritic cells [51,54]. In line with these studies, our data strengthens the close association between up-regulated complement activation and HIV disease progression at the genetic level in primary CD4+ T cells, and the impacts of innate immunity on HIV pathogenesis warrants further investigation. Together, these observations imply that different cell subsets differ in their pace towards disease progression and the way they maintain distinct immunologic interaction with HIV during the disease course. Thus, the specific HIV disease stage may bear cell type-specific transcriptomic signatures, which is evident from this study.

Conclusions

In summary, this study is the first to identify a network of a large panel of pathways functionally connected by mitochondria as a transcriptional signature of HIV disease progression in primary CD4+ and CD8+ T cells. This signature contains 43 metabolic pathways closely articulated with TCA cycle and OXPHOS pathways pointing towards mitochondrial dysfunction. The significance of mitochondrial dysfunction is further strengthened by the detection of coordinately up-regulated genes involved in mitochondria-mediated cell apoptosis in both CD4+ and CD8+ T cells in the VIR group (VIR versus BDL). Mitochondria-mediated cell apoptosis is negatively regulated by the AKT pathway top ranked for the LTNP, which could contribute to cell survival in the LTNP. Along with the AKT pathway, MAPK and WNT pathways are also closely associated with the LTNP, which may contribute to cell survival and stronger anti-viral responses via Th1 polarization, IFN-γ regulation, and cytotoxicity activity. Comparisons between CD4+ and CD8+ T cells revealed that the CD8+ T cell transcriptome shifts after the viral load becomes detectable, but this occurs earlier in CD4+ T cell transcriptomes. Another transcriptional signature unique to CD4+ T cells is the complement activation in the VIR group versus BDL/LTNP. Overall, these data offer new comparative insights into HIV disease progression from the aspect of HIV-host interactions at the transcriptomic level, which will facilitate the understanding of the genetic basis of transcriptomic interaction of HIV in vivo and how HIV subverts the human gene machinery at the individual cell type level. Further studies on the regulation of these pathways and the corresponding core enrichment genes may provide a detailed understanding of the molecular mechanisms involved, which may also aid the development of therapeutic interventions. Future therapeutic interventions aiming at preserving mitochondrial function could be clinically beneficial. Building up database of the pathway interactions will definitely aid the understanding of the interconnections between various pathways, which will ultimately enable the integration of various molecular mechanisms into a system level.

Methods

Patient profiles and collection protocol

Four HIV infected long-term non-progressors (LTNP; n = 4), five HIV+ patients on HAART with below detectable level of plasma viremia (BDL; n = 5), and five viremic HIV+ patients on HAART (VIR; n = 5) along with five healthy HIV seronegative individuals (NEG; n = 5) were studied. No single individual had CCR5-Δ32 homozygous mutation and there is no statistically significant difference in the prevalence of CCR5-Δ32 heterozygous between the study groups. The infection time for L1, L2 and L3 are >20 years, and L4 >14 years. These treatment-naïve LTNP have maintained high CD4+ T cell counts (> 500 cells/μl) and below detectable plasma viremia (< 50 HIV RNA copies/ml plasma) except one patient (L4) with very low plasma viremia (57 HIV RNA copies/ml plasma) (Table 1). Patients in the VIR group were on HAART and had detectable plasma viremia and CD4+ T cell counts <500 cells/μl, whereas patients in the BDL group showed no detectable viremia while on HAART. These patients received two NRTIs (zidovudine, lamivudine, stavudine, emtricitabine, tenofovir) in association with one or two protease inhibitors (darunavir, ritonavir, indinavir, saquinavir, atazanavir). Eleven patients came from the HIV clinic at Westmead Hospital and three patients plus the five healthy controls came from the Australian Red Cross Blood Service in Sydney. This study was approved by the Sydney West Area Health Services
with an integrated step of on-column DNase treatment. A single blood sample (10-20 ml in EDTA) was obtained from each patient. After separation of plasma, PBMC were isolated immediately after obtaining blood samples by Ficoll-gradient centrifugation and purified. This aspect was strictly followed in our experiments because of previously described lower RNA yields and possible changes in gene expression profiles upon storage of blood [55]. CD4+ and CD8+ T cells were then obtained by positive isolation with antibody-conjugated magnetic beads according to the manufacturer’s instructions (Dynal Biotech, Oslo, Norway). Flow-cytometric analysis performed on separated CD4+ and CD8+ T cell populations demonstrated that 99.2% ± 0.165 (mean ±SD) and 99.1% ± 0.128 (mean ±SD) of purified CD4+ and CD8+ cells were single positive for the CD4 and CD8 marker, respectively [56]. In positively isolated CD8+ cell population, >97% cells were CD3 positive as shown by flow cytometry in a previous study [18]. Thus, the very low percentage of NK cells in CD8+ cell population would have negligible effect on the results. Total RNA was isolated from purified cells using RNeasy Mini kit (Qiagen Pty Ltd., Clifton Hill, Victoria, Australia) RNA isolation from purified cells using RNeasy Mini kit (Qiagen Pty Ltd., Clifton Hill, Victoria, Australia). Flow-cytometric analysis performed on separated CD4+ and CD8+ T cell populations demonstrated that 99.2% ± 0.165 (mean ±SD) and 99.1% ± 0.128 (mean ±SD) of purified CD4+ and CD8+ cells were single positive for the CD4 and CD8 marker, respectively [56]. In positively isolated CD8+ cell population, >97% cells were CD3 positive as shown by flow cytometry in a previous study [18]. Thus, the very low percentage of NK cells in CD8+ cell population would have negligible effect on the results. Total RNA was isolated from purified cells using RNeasy Mini kit (Qiagen Pty Ltd., Clifton Hill, Victoria, Australia) with an integrated step of on-column DNase treatment.

**cRNA preparation, microarray hybridization and scanning**

RNA quality was checked by Agilent Bioanalyzer and RNA Integrity Scores are higher than 7 for all the samples. cRNA amplification and labeling with biotin were performed using Illumina TotalPrep RNA amplification kit (Ambion, Inc., Austin, USA) with 250 ng total RNA as input material. cRNA yields were quantified with Agilent Bioanalyzer and 1.5 µg cRNAs were hybridized to the Sentrix Human-6 v2 Expression BeadChips (Illumina, Inc., San Diego, USA). Each chip contains six arrays and each array contains >48,000 gene transcripts, of which, 46,000 derived from human genes in the National Center for Biotechnology Information (NCBI) Reference Sequence (RefSeq) and UniGene databases. All reagents and equipment used for hybridization were purchased from Illumina, Inc. According to the manufacturer’s protocol, cRNA was hybridized to arrays for 16 hours at 58°C before being washed and stained with streptavidin-Cy3. Then the beadchips were centrifuged to dry and scanned on the Illumina BeadArray Reader confocal scanner.

**Analysis of differentially expressed genes**

The quality of the entire data set was assessed by box plot and density plot of bead intensities, density plot of coefficient of variance, pairwise MAplot, pairwise plot with microarray correlation, cluster dendrogram, and non-metric multidimensional scaling (NMDS) using R/ Bioconductor and the lumi package [22]. Based on the quality assessment, all 38 samples were deemed suitable for further analysis. Data normalization was performed using a variance-stabilising transform (VST) and a robust spline normalization (RSN) implemented in the lumi package for R/Bioconductor [22,57]. To reduce false positives, unexpressed genes (based on a detection p value cut-off 0.01) were removed from the dataset. A linear model fit in conjunction with an empirical Bayes statistics were used to identify candidate differentially expressed (DE) genes [23]. Adjustment for multiple testing was performed using the Bonferroni adjustment. For both CD4+ and CD8+ T cells, pairwise comparisons from the 4 study groups (BDL vs NEG, VIR vs NEG, LTNP vs NEG, BDL vs LTNP, VIR vs LTNP, BDL vs VIR) were carried out and candidate DE genes with fold change >2 and B-statistic > 0 were identified for each of the comparisons.

To identify the enriched functional categories from the DE genes, Gene Ontology (GO) Tree from WebGestalt (Web-based Gene SeT Analysis Toolkit) was used to identify GO categories with significantly enriched gene numbers [58]. The hypergeometric test was used to calculate the statistic for each category and all genes from human were used as the reference gene set. GO categories with at least 2 genes and p < 0.01 are identified as enriched and colored red in the GOTree. In GOTree, O stands for observed gene number in the category; E for expected gene number in the category; R for ratio of enrichment for the category; and P for p value calculated from the statistical test given for the categories with R > 1 to indicate the significance of enrichment.

**Gene set enrichment analysis**

To further understand the biological meanings underlying the transcriptome data from various HIV+ disease groups, a complement approach, gene set enrichment analysis (GSEA) was used [24]. Instead of selecting single DE genes, this method analyzed the entire transcriptome data to identify genes coordinately regulated in predefined gene sets from various biological pathways. For each pairwise comparison (BDL versus LTNP, VIR versus LTNP, BDL versus VIR) for both CD4+ and CD8+ T cells, GSEA was performed using the normalized data of entire 48,000 transcripts (GSEA version 2.0, Broad Institute http://www.broad.mit.edu/gsea). First, a ranked list was obtained by ranking all genes according to the correlation between their expression and the group distinction using the metric signal to noise ratio. Then the association between a given gene set and the group was measured by the non-parametric running
sum statistic termed the enrichment score (ES), which was calculated by walking down the ranked list, increasing when encountering a gene in the given gene set and decreasing when encountering a gene not in the gene set. To estimate the statistical significance of the ES, a nominal p value was calculated by permuting the genes 1,000 times. To adjust for multiple hypothesis testing, the maximum ES was normalized to account for the gene set size (NES) and the false discovery rate (FDR) corresponding to each NES was calculated. The gene sets used are from Molecular Signatures Database (MsigDB) [24], catalog C2 functional sets, subcatalog canonical pathways, which include 639 gene sets from pathway databases (version 2.5, updated by April, 2008). These gene sets are canonical representations of a biological process compiled by domain experts such as BioCarta, GenMAPP, and KEGG.

Real-time quantitative PCR
Purified total cellular RNA was reverse transcribed using oligo d(T) and Superscript III followed by RNase H treatment (Invitrogen Life Technologies). The cDNA was then subject to real-time quantitative PCR with SYBR Green (Invitrogen Life Technologies). The cDNA was then subject to real-time quantitative PCR with SYBR Green (Invitrogen Life Technologies). The primer and SYBR Green (Invitrogen Life Technologies) using Mx3005P™ QPCR System (Stratagene). The relative quantitation method was used to evaluate the expression of selected genes with the housekeeping gene GAPDH as an internal control and the normalizer for all data.

Additional material

Additional file 1: Differentially expressed genes between HIV+ disease groups. List of differen tally expressed genes between HIV+ disease groups.

Additional file 2: Core enrichment genes in the enriched pathways. List of core enrichment genes in the enriched pathways.

Additional file 3: Core enrichment genes (highlighted in red) in the complement and coagulation cascade pathway with highlighted genes.

Additional file 4: Top ranked gene sets enriched in the LTNP group. List of top ranked gene sets enriched in the LTNP group.

Acknowledgements
JQ Wu received a University of Sydney Australian Postgraduate Award and a top up scholarship from the Millennium Foundation, Westmead. This work was funded by the AIDS Foundation Budget and a NHMRC Career Development Grant (503807) to NKS. BW was funded by a NHMRC Career Development Award Research Fellowship. We thank Amanda Croft for the help with Illumina beadchip technology, Drs. Choo Beng Chew and Jenny Learmont for patient samples.

Author details
1Retroviral Genetics Division, Center for Virus Research, Westmead Millennium Institute, University of Sydney, Darcy Road, Westmead, NSW 2145, Australia. 2Department of Virology, Centre for Infectious Diseases and Microbiology Laboratory Services, ICPMR, Westmead Hospital, Westmead, NSW 2145, Australia. 3Immunovirology Laboratory, Australian Red Cross Blood Service, Sydney, NSW 2000, Australia. 4School of Mathematics and Statistics, University of Sydney, NSW 2006, Australia.

Authors’ contributions
JQW fully performed the work, analyzed data, and wrote the paper; DED provided the patients, assisted with clinical follow up and details; WBD assisted with LTNP samples, intellectual input with LTNP biology, assistance with writing; YHY assisted with the mathematical and statistical sections; BW assisted with writing and technical aspects of the work and NKS conceived the idea, supervised the work and assisted with writing the manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 15 December 2010 Accepted: 16 March 2011 Published: 16 March 2011

References
1. Taylor JM, Fahey JL, Detels R, Gorgj J: CD4 percentage, CD4 number, and CD4/CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 1989, 2:114-124.
2. Rosenberg ES, Billinglsey JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447-1450.
3. Clerici M, Hakim FT, Venzon DJ, Blatt S, Hendrix CW, Wynn TA, Shearer GM: Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 1993, 91:759-765.
4. Benzelinsky J, Bensussan A, Caste KB, Bourge FJ, Cheynier R, Lurhuma Z, Salau J, Gallo RC, Shearer GM, Zagyv D: Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature 1988, 334:706-708.
5. Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, Maino VC, Picker LJ: HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999, 5:518-525.
6. Di Mascio M, Sereti I, Matthews LT, Nataaraan J, Adelsberger J, Lempicki R, Yoder C, Jones E, Chow C, Metcalf JA, et al: Naive T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion. J Virol 2006, 80:2665-2674.
7. Haase AT: Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annual Review of Immunology 1999, 17:625-656.
8. McCune JM: HIV-1: the infective process in vivo. Cell 1991, 64:351-363.
9. Saksena NK, Wu JQ, Lau K, Zhou L, Soedjono M, Wang B: Soluble Factors Mediating Inmate Immune Responses to HIV Infection. Bentham Science Publishers, 2010.
10. Mackiewicz CE, Craik CS, Levy JA: The CD8+ cell noncytotoxic anti-HIV response can be blocked by protease inhibitors. Proc Natl Acad Sci USA 2003, 100:3433-3438.
11. Geldmacher C, Currier JR, Herrmann E, Haule A, Kuta E, McCutchan F, Njovu L, Geis S, Hoffmann O, Maboko L, et al: CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients. J Virol 2007, 81:2440-2448.
12. Muxey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ: Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997, 337:1267-1274.
13. Herbein G, Mahlknecht U, Batliwalla F, Gregersen P, Pappas T, Butler J, Brien WA, Verdin E: 'Latent' HIV-1 infection: the infective process in vivo. Nature 1998, 395:189-194.
14. Lewis DE, Tang DS, Adu-Oppong A, Schober W, Rodgers JR: Anergy and apoptosis in CD8+ T cells from HIV-infected persons. Journal of Immunology 1994, 153:412-420.
15. Giri MS, Nebozyn M, Showe L, Montaner LJ: Microarray data on gene modulation by HIV-1 in immune cells: 2000-2006. J Leukoc Biol 2006, 80:1031-1043.
16. Chun TW, Justement JS, Lempiäki RA, Yang J, Dennis G Jr, Hallahan CW, Sanford C, Pandya P, Liu S, McLaughlin M, et al: Gene expression and viral production in latently infected, resting CD+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci USA 2003, 100:1908-1913.

17. Díaz L, Stone M, Mackiewicz C, Levy J: Differential gene expression in CD8+ cells exhibiting noncytotoxic anti-HIV activity. Virology 2003, 311:400-409.

18. Martínez-Marino B, Foster H, Hao Y, Levy J: Differential gene expression in CD8+ cells from HIV-1-infected subjects showing suppression of HIV replication. Virology 2007, 362:217-225.

19. Hrycza MD, Kovacs C, Lourty M, Haljenny R, Heisler L, Yang S, Wilkins O, Ostrowski M, Der SD: Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8+ T cells. J Virol 2007, 81:9477-9486.

20. Wu JQ, Dwert DE, Dyer WR, Yang YH, Wang B, Saksena NK: Transcriptional profiles in CD8+ T cells from HIV+ progressors on HAART are characterized by coordinated up-regulation of oxidative phosphorylation enzymes and interferon responses. Virology 2008, 360:128-135.

21. Wu JQ, Wang B, Saksena NK: Transitory viremic surges in a human immunodeficiency virus type 1-infected patient: does an alpha- and beta- elite controller can shift the cellular transcriptome profile: a word of caution for microarray studies. J Virol 2008, 82:10326-10327.

22. Du P, Kibbe WA, Lin SM: lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008, 24:1547-1548.

23. Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3:Article 3.

24. Subramanian A, Tamayo P, Mootha VK, Mukhejee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:15545-15550.

25. Ciccola C, Arthos J, Selig SM, Denni G Jr, Hassack DA, Van Ryk D, Spangler ML, Steenbeke TD, Khazanie P, Gupta N, et al: HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication. Proc Natl Acad Sci USA 2002, 99:9380-9385.

26. Chan EY, Qian WJ, Diamond DL, Liu T, Gritsenko MA, Monroe ME, Distefano PJ, Hallahan CW, Sanford C, Pandya P, Liu S, McLaughlin M, et al: Gene expression and viral production in latently infected, resting CD+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci USA 2003, 100:1908-1913.

27. Ringrose JH, Jeeninga RE, Berkhout B, Speijer D: HIV-1 protease processes prosapase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation. Cell Death Differ 2002, 9:1712-1746.

28. Falk MJ, Zhang Z, Rosenjacak JR, Ninism I, Dakhin L, Ninism I, Sederinsky MM, Yudkoff M, Morgan PG: Metabolic pathway profiling of mitochondrial respiratory chain mutants in C. elegans. Mol Gen Metab 2008, 93:388-397.

29. Moretti S, Marcellini S, Boschi A, Famularo G, Santini G, Alesse E, Steinberg SM, Cifone MG, Kroemer G, De Simone C: Apoptosis and apoptosis-associated perturbations of peripheral blood lymphocytes during HIV infection: comparison between AIDS patients and asymptomatic long-term non-progressors. Clin Exp Immunol 2000, 122:382-384.

30. Peraire J, Miro O, Saumoy M, Domingo P, Pedrioli E, Villarroy F, Martinez E, Lopez-Dupla M, Garrabou G, Sambeat MA, et al: HIV-1-infected long-term non-progressors have milder mitochondrial impairment and lower mitochondrially-driven apoptosis in peripheral blood mononuclear cells than typical progressors. Curr HIV Res 2007, 5:467-473.

31. Ayyavoo V, Mahalingam S, Rafael Y, Kudchodkar S, Chang D, Nagashumugam T, Williams W, Weiner DB: HIV-1 viral protein R (Vpr) regulates viral replication and cellular proliferation in T cells and monocytoid cells in vitro. J Leukoc Biol 1997, 62:93-99.

32. Cohenblum M, Kider JH, Brown JN, Osher TR, Baker HV, Papp MP, Slaeams JW, Goodenow MM: Impact on genetic networks in human macrophages by a CCR5 strain of human immunodeficiency virus type 1. J Virol 2004, 78:11477-11486.

33. Nimmich M, Yao XJ, Bachand F, Rougais N, Cohen EAH: Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection. J Virol 1999, 73:4101-4109.

34. Andersen JL, DeHart JL, Zimmerman ES, Ardon O, Kim B, Jacquot G, Benichou S, Plantefies V: HIV-1 Vpr-induced apoptosis is cell cycle dependent and requires Bax but not BAX. PLoS Pathog 2006, 2:e127.

35. Kowalczyk JE, Zablocka P: Protein kinases in mitochondria. Postepy Biochem 2008, 54:209-216.

36. Oh SW, Mukhopadhyay A, Srivatsa K, Jiang D, Fang J, Davis RJ, Tissenbaum HA: GSK3beta. Science 1998, 280:1261-1264.

37. Mittler R, Sun L, Zilinskas A, Zhu C, Menke A, Aronovitz R, Lark M, Zeiger J: Mitochondrial Ca2+ homeostasis and ROS production: a role for the enolase. Proc Natl Acad Sci USA 2004, 101:12269-12274.

38. Androulakis IP, Moraes CT: Mitochondrial Ca2+ homeostasis and ROS production: a role for the enolase. Proc Natl Acad Sci USA 2004, 101:12269-12274.

39. Androulakis IP, Moraes CT: Mitochondrial Ca2+ homeostasis and ROS production: a role for the enolase. Proc Natl Acad Sci USA 2004, 101:12269-12274.

40. Androulakis IP, Moraes CT: Mitochondrial Ca2+ homeostasis and ROS production: a role for the enolase. Proc Natl Acad Sci USA 2004, 101:12269-12274.

41. Androulakis IP, Moraes CT: Mitochondrial Ca2+ homeostasis and ROS production: a role for the enolase. Proc Natl Acad Sci USA 2004, 101:12269-12274.

42. Androulakis IP, Moraes CT: Mitochondrial Ca2+ homeostasis and ROS production: a role for the enolase. Proc Natl Acad Sci USA 2004, 101:12269-12274.

43. Androulakis IP, Moraes CT: Mitochondrial Ca2+ homeostasis and ROS production: a role for the enolase. Proc Natl Acad Sci USA 2004, 101:12269-12274.

44. Androulakis IP, Moraes CT: Mitochondrial Ca2+ homeostasis and ROS production: a role for the enolase. Proc Natl Acad Sci USA 2004, 101:12269-12274.

45. Androulakis IP, Moraes CT: Mitochondrial Ca2+ homeostasis and ROS production: a role for the enolase. Proc Natl Acad Sci USA 2004, 101:12269-12274.

46. Androulakis IP, Moraes CT: Mitochondrial Ca2+ homeostasis and ROS production: a role for the enolase. Proc Natl Acad Sci USA 2004, 101:12269-12274.

47. Androulakis IP, Moraes CT: Mitochondrial Ca2+ homeostasis and ROS production: a role for the enolase. Proc Natl Acad Sci USA 2004, 101:12269-12274.

48. Androulakis IP, Moraes CT: Mitochondrial Ca2+ homeostasis and ROS production: a role for the enolase. Proc Natl Acad Sci USA 2004, 101:12269-12274.

49. Androulakis IP, Moraes CT: Mitochondrial Ca2+ homeostasis and ROS production: a role for the enolase. Proc Natl Acad Sci USA 2004, 101:12269-12274.

50. Androulakis IP, Moraes CT: Mitochondrial Ca2+ homeostasis and ROS production: a role for the enolase. Proc Natl Acad Sci USA 2004, 101:12269-12274.
55. Lyons P, Koukoulaki M, Hatton A, Doggett K, Woffendin H, Chaudhry A, Smith K: Microarray analysis of human leucocyte subsets: the advantages of positive selection and rapid purification. *BMC Genomics* 2007, 8:64.
56. Potter SJ, Lemey P, Achaz G, Chew CB, Vandamme AM, Dwyer DE, Saksena NK, Potter SJ, Lemey P, Achaz G, et al: HIV-1 compartmentalization in diverse leukocyte populations during antiretroviral therapy. *J Leukoc Biol* 2004, 76:562-570.
57. Lin SM, Du P, Huber W, Kibbe WA: Model-based variance-stabilizing transformation for Illumina microarray data. *Nucleic Acids Res* 2008, 36:e11.
58. Zhang B, Kirov S, Snoddy J: WebGestalt: an integrated system for exploring gene sets in various biological contexts. *Nucleic Acids Res* 2005, 33:W741-748.

doi:10.1186/1742-4690-8-18
Cite this article as: Wu et al. Genome-wide analysis of primary CD4+ and CD8+ T cell transcriptomes shows evidence for a network of enriched pathways associated with HIV disease. *Retrovirology* 2011 8:18.